Gland Pharma requests shareholders to update email addresses
Gland Pharma Limited requested shareholders to register or update their email addresses to facilitate the electronic delivery of general meeting notices, annual reports, and other statutory communications. This request was made in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders holding physical shares must contact the company's Registrar and Transfer Agent or the company directly, while those with dematerialised shares must update their details with their Depository Participant.
*this image is generated using AI for illustrative purposes only.
Gland Pharma Limited has requested its shareholders to register or update their email addresses to ensure the delivery of general meeting notices, annual reports, and other statutory communications in electronic form. The company issued this notice to comply with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with the publication appearing in newspapers on June 10, 2026.
The company stated that shareholders holding shares in physical mode who have not yet registered or updated their email addresses must do so immediately. These members are required to send their Folio Number and a valid email address to either the company's Registrar and Transfer Agent, MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), or directly to Gland Pharma Limited via email.
For shareholders holding shares in dematerialised mode, the company has directed them to register or update their email addresses with the Depository Participant where their demat accounts are maintained. This step is necessary to ensure seamless electronic communication regarding corporate actions and statutory documents.
The notice was signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer of Gland Pharma Limited, on June 09, 2026. The communication was disseminated to both BSE Limited and the National Stock Exchange of India Limited for their information and records.
Contact Details for Updates
| Shareholder Type | Action Required | Contact Point |
|---|---|---|
| Physical Mode | Send Folio No. and valid e-mail | rnt.helpdesk@in.mpms.mufg.com or investors@glandpharma.com |
| Dematerialised Mode | Update e-mail with Depository Participant | Depository Participant |
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.92% | +1.92% | +17.88% | +33.71% | +34.51% | -28.14% |
How will this transition to mandatory electronic communication impact the engagement levels of retail shareholders holding physical shares?
Could this initiative signal Gland Pharma's broader strategy to phase out physical share certificates entirely in the near future?
What penalties or restrictions might shareholders face if they fail to comply with the email registration mandate by the deadline?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
